engleski

NONALCOHOLIC FATTY LIVER DISEASE – A MULTISYSTEM DISEASE

AIM:Our aim was to investigate the incidence of NAFLD in patients with chronic kidney disease (CKD), patients with adenomatous polyps and colorectal cancer (CRC). We were interested to explore the association between NAFLD and decreased kidney function in patients CKD grade III and IV, as well as in renal transplant recipients (RTRs). Furthermore, we were interested to analyze whether the presence of NAFLD is associated with a higher cardiovascular (CVD) risk in hemodialysis (HD) patients and RTRs METHODS:We examined 206 CKD patients ; 62 CKD patients grade III and IV, 71 HD patients and 73 RTRs. Fifty patients with adenomatous polyps and 13 with CRC take a part in this study as well. Anthropometric measurement, biochemical test for liver, kidney and metabolic function, and transient elastography (Fibroscan®-CAP) were assessed. RESULTS:Out of 62 CKD patients grade III and IV, 85.5% had NAFLD. Furthermore, NAFLD was present in 57.5% of RTRs. The severity of liver steatosis was negatively correlated with kidney function in CKD and RTRs. NAFLD was found in 52.1% of HD patients. RTRs and HD patients with NAFLD shows more carotid atherosclerosis than RTRs and HD patients without NAFLD. Fourthly-five (90%) patients with adenomatous polyps and 13 (84.6%) patients with CRC had NAFLD. Thirty-eight out of 50 patients with polyps had advanced histological findings of their polyps ; 36 of them had NAFLD. Twenty-one patients had polypus of 10 mm or more in diameter and all of them had NAFLD. CONCLUSION: Our results support the idea that NAFLD is a multisystem disease.

nonalcoholic fatty liver disease; multisystem disease

nije evidentirano